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ABSTRACT
Background. Left atrial appendage (LAA) closure represents an alternative strategy to oral anticoagulants in 
thromboembolic prophylaxis in patients with atrial fibrillation (AF). The LAA closure with the WATCHMAN™ 
device has been proved to be non-inferior to warfarin therapy. Nevertheless, this strategy is associated with 
numerous periprocedural complications. This study was conducted to determine whether the experience 
of the operating team affects the duration of the procedure and its complication rate. 
Methods. This retrospective single-centre study examined LAA percutaneous closure procedures in 
43 consecutive AF patients with contraindications to oral anticoagulation (13 female, 30 male; mean age 
70.98 ± 10.69 years). All device implantations were performed by two operators using the WATCHMAN™ 
device and the result was assessed by two echocardiographers. We compared the first 22 (group A) with 
the subsequent 21 procedures (group B).
Results. For group B, a decrease in the overall procedure time (PT) by 28% (from 83.41 min ± 36.49 to 
59.76 min ± 21.70; p = 0.006) was found, with a subsequent reduction in fluoroscopy time (FT) by 33% 
(from 16.59 min ± 7.25 to 11.2 min ± 7.21; p = 0.019) and the volume of contrast medium (CV) by 40% 
(from 129.14 mL ± 79.81 to 78.05 mL ± 33.82; p = 0.004). The incidence of periprocedural adverse events 
and complications was 55% (12 patients) in group A and 33% (7 patients) in group B. 
Conclusions. The increasing operators’ and echocardiographers’ experience in LAA closure is associated 
with reduction in procedure time, fluoroscopy time and contrast volume. 
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Introduction
Atrial fibrillation (AF) is the most common sustained 
arrhythmia [1]. It applies to 2% of general population of 
Europe and North America and its incidence increases 
with age, from about 4% in those aged 60–70 years to 
more than 15% in those aged 80 years or older [2]. AF 
may lead to thrombus formation and possible thrombo-
embolic complications. The estimated risk of ischemic 
stroke in patients with AF is 5% per year and is 5-fold 
higher than in the general population [3]. Approximately 
90% of atrial thrombi in non-rheumatic AF are formed 
within the left atrial appendage (LAA) [4]. 
There are several pharmacological antithrombotic 
options such as warfarin and the novel oral anticoagu-
lants (NOACs). However, at least 20% of patients have 
contraindications to warfarin therapy [5]. NOACs, with 
their efficacy comparable to warfarin, have potentially 
a better safety profile. Nevertheless, the nature of anti-
coagulation carries an inseparable risk of bleeding [6]. 
LAA occlusion represents an alternative strategy for 
thromboembolic prophylaxis in patients with contra-
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indications to OACs. The PROTECT-AF randomized 
clinical trial demonstrated that LAA closure with the 
WATCHMAN device (Boston Scientific, Natick, Massa-
chusetts) is non-inferior to warfarin therapy, and the re-
cent follow-up publication showed the superiority of LAA 
occlusion [7, 8]. However, the LAA closure sustained an 
increased number of procedure-related safety events [8]. 
A  recent indirect comparison of the data from the 
PROTECT-AF and RE-LY trial revealed that the WATCH-
MAN device would fail to meet non-inferiority when 
compared with one of the NOACs — dabigatran [9]. 
However, a prospective, randomized, head-to-head trial 
is required to ultimately clarify this issue [9]. 
The LAA closure has become a  reasonable and 
increasingly accessible option for patients with AF, par-
ticularly for those at high risk of bleeding. Moreover, the 
majority of costs related to this procedure are borne in 
the first year, while costs for pharmaceutical strategies 
continue to accrue year-on-year. Thus, LAA closure 
represents an opportunity for long-term savings to 
healthcare systems [10]. Nevertheless, interventional 
procedures are associated with numerous periproce-
dural adverse events and complications such as pericar-
dial effusion, bleeding or contrast induced nephropathy 
which correlate with the duration of the procedure. 
This study was conducted to investigate whether the 
duration of the percutaneous LAA occlusion procedure, 
fluoroscopy time and volume of contrast medium used 
during the procedure as well as the periprocedural 
complication rate are associated with the experience 
of the operators and echocardiographers. 
Methods
Study population
This retrospective, single-centre study examined 
LAA percutaneous closures in 43 patients performed in 
the Cardiology Department of University Hospital No. 1 
in Bydgoszcz, Poland between June 2013 and March 
2015, listed chronologically. All information required 
for this study was obtained from the patients’ medical 
records. The indication for LAA closure was a formal 
contraindication to oral anticoagulation. Table 1 shows 
the baseline clinical characteristics of the study cohort.
Procedure details
All device implantations were performed by two 
operators (AS, SS) using the WATCHMAN device. In 
all cases the standard pre-procedural assessment 
included transesophageal echocardiography (TOE) 
aimed at the detection of intracardiac thrombi (all pa-
tients were thrombi-free) and the evaluation of width 
and depth of the LAA as well as the number and po-
sition of different lobes at different plane angulations 
ranging between 0° and 135°. At the start of the LAA 
occlusion programme all procedures were performed 
under general anaesthesia, while subsequent cases 
were performed on sedation only. Implantations of the 
devices were performed via the right femoral vein and 
transseptal puncture. A  careful TOE evaluation was 
conducted after each device implantation. When the 
result of the implantation was optimal, the procedure 
was stopped; otherwise, the device was repositioned 
or replaced. The outcome of all LAA occlusions was 
optimal. Table 2 presents periprocedural adverse events 
and complications. 
Contrast-induced nephropathy was defined as acute 
renal failure in patients with normal kidney function be-
fore the intervention using a contrast agent or significant 
deterioration of renal function in patients previously 
diagnosed with chronic renal failure. Significant de-
terioration in renal function was defined, on the basis 
of laboratory standards, as a  decrease in creatinine 
clearance by ≥ 25% or an increase in the concentration 
of creatinine by ≥ 25% or ≥ 0.5 mg/dL (44.2 mmol/L) 
Table 2. Periprocedural adverse events and 
complications
Character Study cohort (n = 43)
Pericardial effusion* 16 (37.1%)
Bleeding** 6 (14%)
Contrast induced nephropathy 6 (14%)
Pulmonary oedema 1 (2.3%)
Hypertension 1 (2.3%)
Thrombus 0 (0%)
Pulmonary embolism 0 (0%)
Stroke 0 (0%)
*Adverse event — all pericardial effusions were minor and did not 
require any intervention; **bleeding includes: 1 bleeding from tonsils 
due to intubation, 1 upper gastrointestinal bleeding and 4 haematomas 
at the puncture site
Table 1. Baseline characteristics of the study cohort
Character Study cohort (n = 43)
Age (years) 70.98 ± 10.69
Male gender 30 (69.8%)
Type of AF
   Paroxysmal 16 (37.2%)
   Persistent 17 (39.5%)
   Permanent 10 (23.3%)
CHADS 2.88 ± 1.45
CHA2DS2-VASc 4.33 ± 1.78
HAS-BLED 2.85 ± 1.09
AF — atrial fibrillation
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in comparison with the value before the intervention 
(during 24–72 h after the administration of contrast 
agent) [11–14]. Post-procedure pericardial effusion was 
based on subjective echocardiographic assessment 
by the same single person (IŚ) in comparison with the 
baseline echocardiography.
Statistical methods
We assessed 3 components of the procedural 
course of LAA closure: procedure time (PT), fluoros-
copy time (FT) and contrast volume (CV) used during 
the procedure. For the purposes of this study it was 
assumed that the higher the procedure number, the 
higher operator’s experience would be. The patients 
were listed chronologically. The data were analysed 
with a dual approach. Firstly, we assessed the learning 
curve (first approach). Additionally, we divided the pa-
tients into 2 groups, comparing the first 22 WATCHMAN 
device implantation procedures (group A) with the 
subsequent 21 procedures (group B) and calculated 
the percentage of reduction in PT, FT and CV (second 
approach). Continuous variables were reported as 
mean ± standard deviation, and categorical variables 
as numbers and percentages. Continuous variables 
were compared using the t-test. Correlations between 
PT, FT, CV and the procedure number were calculated 
using the Pearson correlation test. P-value < 0.05 was 
considered statistically significant. Statistical analysis 
was performed using Statistica PL software version 8.0.
Results
First approach
We found statistically significant reductions in PT 
(p = 0.006), FT (p = 0.019) and CV (p=0.004) along 
with the increasing operators’ and echocardiographers’ 
experience (Fig. 1). The correlation between the pro-
Figure 1A. First approach. Grey marks indicate patients with periprocedural adverse events and complications; B. First 
approach. Grey  marks indicate patients with periprocedural adverse events and complications; C. First approach. Grey 
marks indicate patients with periprocedural adverse events and complications. 
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Table 3. Second approach
Variable Procedure time [min] Fluoroscopy time [min] Contrast volume [mL]
Overall average 71.86 ± 31.77 13.96 ± 7.57 104.19 ml ± 66.07
Group A average 83.41 ± 36.49 16.59 ± 7.25 129.14 ml ± 79.81
Group B average 59.76 ± 21.70 11.2 ± 7.21 78.05 ml ± 33.82
Reduction rate (%) 28 33 40
p-value p = 0.006 p = 0.019 p = 0.004
cedure number and PT as well as CV was moderate 
[r = (–0.41); r = (–0.43), respectively], while only a weak 
correlation was found between FT and the procedure 
number [r = (–0.35)].
Second approach
The overall average PT was 71.86 min ± 31.77. The 
average PT was 83.41 min ± 36.49 in group A  and 
59.76 min ± 21.70 in group B, translating into a 28% 
reduction in PT.
The overall average FT was 13.96 min ± 7.57. The 
average FT in group A  was 16.59 min ± 7.25 and 
11.2 min ± 7.21 in group B, with a  reduction in FT 
by 33%.
The overall average CV was 104.19 ml ± 66.07, 
with the average volume of 129.14 mL ± 79.81 in 
group A and 78.05 mL ± 33.82 in group B, resulting in 
a reduction of CV by 40%. 
The number of patients with periprocedural adverse 
events and complications in group A was 12 (55%) and 
7 (33%) in group B (Tab. 3). 
Discussion
The percutaneous LAA closure with the WATCHMAN 
device has been proved not only to be superior to warfarin 
therapy [8], but also feasible [15] and relatively safe [8, 16]. 
However, safety data on percutaneous LAA closure arise 
from centres with considerable expertise in the procedure 
or from clinical trials which might not be reproducible in 
general clinical practice. Badheka et al. [17] demonstrat-
ed that the frequency of in-hospital adverse outcomes 
associated with this procedure is higher in the real-world 
population than in the clinical trials (Fig. 2).
LAA occlusion is often a difficult procedure due to 
the three-dimensional variable nature of the LAA anat-
omy [18]. Numerous studies reported relatively high 
rates of periprocedural complications in patients who 
underwent this procedure [7, 8, 15]. Reddy et al. [8] and 
Maisel [19], on the other hand, implied that the compli-
cations associated with this procedure are related to the 
operator’s lack of experience and that they are decreas-
Figure 2. Average procedure time (A) and fluroscopy time 
(B) and contrast volume (C)
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ing over time following the learning curve. The overall 
average FT in our study was 13.96 min ± 7.57. Similar 
FT (13.7 ± 6.7 min) was reported by Gafoor et al. [17] 
who used the Amplatzer Cardiac Plug (ACP) in a highly 
experienced German centre. However, it should be 
highlighted that the FT in our centre significantly de-
creased to 11.2 min ± 7.21 in group B (last 21 patients). 
It has been shown that further PT reduction may be 
achieved using the “shape-the-sheath” method [18]. 
This method helps to conform delivery systems to obtain 
better access to the LAA and ensure stable position. 
However, further experience with this procedure optimi-
zation technique is warranted. Early and late outcome 
can be also related to the method of LAA occlusion. 
According to an experimental study performed by Kar 
et al., [20] LAA closure with the Watchman device does 
not obstruct or impact the adjacent heart structures and 
is associated with a favourable local healing response 
as compared with the Amplatzer Cardiac Plug [20].
Our study suggests that not only adverse events and 
complications but also the duration of the procedure 
depends on both operators’ and echocardiographers’ 
training level, and potentially on the method of anaes-
thesia. These two factors might be attributable to each 
other, however, further studies are required to prove 
this thesis.
The clinical implication of our study is that as long 
as there are relatively small target groups of patients 
qualified for LAA closure, the procedures should be 
performed only in a limited number of centres providing 
highly qualified staff in order not to expose patients 
to the potential risk factors resulting from excessive 
prolongation of the procedure duration. However, the 
demand for skilled operators and echocardiographers 
is likely to grow soon, as LAA closure is a highly prom-
ising and effective alternative to oral anticoagulation in 
patients with atrial fibrillation and might become more 
widespread in the near future.
Conclusions
The operator’s and echocardiographer’s experience 
in left atrial appendage closure with the WATCHMAN 
device influences the procedure duration. We noticed 
a statistically significant reduction of PT, FT and CV. 
The effect of the learning curve observed in this study 
has important implications for patient safety.
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